rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Ook SIRNA

1.786 Posts
Pagina: «« 1 ... 78 79 80 81 82 ... 90 »» | Laatste | Omlaag ↓
  2. ludwig mack 8 februari 2006 23:42

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    Last Trade: 4.36
    Trade Time: 4:00PM ET
    Change: 0.13 (2.90%)
    Prev Close: 4.49
    Open: 4.50
    Bid: 4.00 x 500
    Ask: 4.75 x 2000
    1y Target Est: 8.00
  4. [verwijderd] 9 februari 2006 17:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Sirna Therapeutics to Webcast Presentations at the BIO CEO & Investor Conference 2006
    Thursday February 9, 8:21 am ET
    Sirna's Chief Medical Officer to Present at Focus Session on The Biotech Impact on Eye Disorders

    In addition, Roberto Guerciolini MD, Sirna's Senior Vice President of Development and Chief Medical Officer will participate in a focus session titled "Ophthalmology: The Biotech Impact on Eye Disorders," also being held at the BIO CEO & Investor Conference 2006, on Wednesday, February 15, 2006 at 8:30 a.m. EST (5:30 a.m. PST).

    mijn gevoel zegt dat sirna met definitieve resultaten komt van fase 1..
  9. ludwig mack 9 februari 2006 22:33

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    wat is er toch met die lange gerekte zinnen ?

    Last Trade: 4.65
    Trade Time: 4:00PM ET
    Change: 0.29 (6.65%) plus
    Prev Close: 4.36
    Open: 4.39
    Bid: 4.45 x 100
    Ask: 4.65 x 400
    1y Target Est: 8.00

    netjes !
  12. ludwig mack 10 februari 2006 14:12

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    1gustaaf schreef:

    Gaat veel beter dan ik verwachtte. Ceo profileert Sirna blijkbaar goed.
    15/2 meer.
    Guus
    kan niet terugvinden de 15e a.s. ?
  13. gustaaf1e 10 februari 2006 15:27

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 02 apr 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    quote:

    ludwig mack schreef:

    [quote=1gustaaf]
    Gaat veel beter dan ik verwachtte. Ceo profileert Sirna blijkbaar goed.
    15/2 meer.
    Guus
    [/quote]

    kan niet terugvinden de 15e a.s. ?
    Zie laatste persbericht. 15 februari 10.30 uur ET presentatie CEO op BIO CEO&Investors Conference 2006 in NY etc.

    groet,
    Guus
  15. ludwig mack 13 februari 2006 18:09

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    mooie opening, maar meteen daarna toch weer een daling;
    ik heb besloten aan de zijlijn te wachten en winst genomen, al heb ik niet de openingsprijs :((
    ik heb er vertrouwen in, maar het kan allemaal nog een erg lang verhaal worden;
    ik blijf het fonds volgen.
    succes !
    groet
  16. [verwijderd] 13 februari 2006 18:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ik nog niet..ik wacht toch ff deze maand af..heb een goed gevoel en ben er vrijwel zeker van dat er meerdere belangrijke persberichten aankomen..

    denk aan resultaten fase 1 om mee te beginnen..

    misschien wat milestonepayments voor het starten van fase 2, en dan nog wat nieuws over de andere produkten
  18. [verwijderd] 13 februari 2006 18:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ik denk dat we sowieso 15 februari resultaten kunnen verwachten van fase 1 tests..gelet op een persbericht van 9 februari waarin het volgende wordt gemeld:

    Sirna's Chief Medical Officer to Present at Focus Session on The Biotech Impact on Eye Disorders

    En als het goed is, was sirna al in december 2005 klaar met de fase 1 voor AMD

    ben benieuwd !
  21. [verwijderd] 15 februari 2006 17:06

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bedoel je het bericht dat CEO Robin in de Board of Directors van Acologix gaat zitten:

    Biopharmaceutical Industry Leader Joins Acologix, Inc. Board of Directors
    Company Leadership Focuses on Next Phase of Corporate Development

    HAYWARD, Calif., Feb 15, 2006 /PRNewswire via COMTEX/ -- Acologix, Inc., a privately held biopharmaceutical company, announced today, the appointment of Mr. Howard W. Robin, President and CEO of Sirna Therapeutics, Inc. to the Acologix Board of Directors. Earlier this month, Acologix closed the second tranche of its approximately $30 Million Series C financing. To date, the company has raised over $75 Million, primarily from Japanese and other Asian institutional investors.
    "We are extremely pleased to welcome Mr. Robin, who has over twenty years of experience in the biopharmaceutical industry," said Yoshi Kumagai, President and CEO of Acologix. "Mr. Robin's experience in managing pharmaceutical development and multimillion dollar commercial operations will make significant contributions to the Company's sustained growth." Added R. Scott Greer, Chairman of the Board, "With the addition of Mr. Robin, Acologix has established a board with the requisite skills and international experience to assist management as the company looks toward a potential future public listing."
    In a position held since 2001, Mr. Robin serves as President and Chief Executive Officer of Sirna Therapeutics (RNAI : sirna therapeutics inc com
    News , chart, profile, more RNAI4.68, +0.06, +1.3%) , a clinical-stage biotechnology company located in San Francisco, CA. Sirna develops RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington's disease, diabetes and oncology.
    "I am delighted to join the Acologix Board and help management build a leading company focused on osteo-renal diseases," said Howard Robin. "With a European Phase III clinical study underway and a U.S. pivotal trial expected to begin later this year, I especially am looking forward to assisting Acologix as it formulates its commercialization strategy."
    Prior to joining Sirna Therapeutics, Mr. Robin was Corporate Vice President and General Manager of the Therapeutics Division, as well as a member of the Executive Committee, of Berlex Laboratories, Inc., the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering, AG. During his twenty-year career at Berlex, Mr. Robin held various positions of increasing responsibility, including Vice President of Finance and Business Development as well as Chief Financial Officer. As General Manager of Therapeutics at Berlex, Mr. Robin was responsible for the clinical development and commercialization of drugs such as Fludara(R) for chronic lymphocytic leukemia and Betaseron(R) for multiple sclerosis, generating worldwide sales in excess of $750 Million. Prior to joining Berlex, Mr. Robin was a senior associate with Arthur Andersen & Co.
    In addition to Mr. Robin, Acologix's board includes R. Scott Greer, a founder, past CEO and current chairman of Abgenix, Inc., Dan Hoth, M.D, a board certified oncologist, past CMO of Arris Pharmaceuticals and Cell Genesys, and past director of Division of AIDS at NIAID, Hatsushi Shimizu, Ph.D., the sole founder and director of Shimizu International Patent Office, Tom Smart, Vice President of Business Development of Xoma Ltd and previously SVP, Corporate Development of GenVec., Aki Watanabe, past managing partner of KPMG Corporate Finance and current managing partner of GCA Corporation, and Yoshi Kumagai, President and CEO of Acologix, Inc.
    About Acologix, Inc.
    Acologix strives to improve patients' lives by developing and commercializing innovative biopharmaceuticals targeting "osteo-renal" (bone and kidney) diseases. Acologix' substantial expertise in identifying and developing therapeutics with unique mechanisms of action in the osteo-renal field will be a key to solving major kidney and bone health problems. Such conditions include chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. These conditions are present in increasing numbers worldwide and require the development of novel therapeutics. In June 2005, Acologix announced a partnership with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (or TRK-820), an anti-pruritic agent for the treatment of uremic pruritus in dialysis patients. A European Phase III pivotal clinical study is underway. Acologix plans to launch a US Phase III trial in late 2006. Acologix' leading hard tissue regeneration compound, AC-100 (Dentonin(R)) is currently under investigation in two Phase II clinical studies in Europe and the United States for the repair of periodontal defects and in dental restorations, respectively. Acologix has raised a total of $77 Million to date, through three rounds of private financing. For further information on Acologix, please refer to the Company's website at www.acologix.com
    This press release contains "forward-looking" statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix's business.
    SOURCE Acologix, Inc.
    Yoshi Kumagai, President and CEO, of Acologix, Inc., phone, +1-510-512-7200, or fax, +1-510-786-1116, or ir@acologix.com www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved.
1.786 Posts
Pagina: «« 1 ... 78 79 80 81 82 ... 90 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.126
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.237
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.899
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.850
Aedifica 3 927
Aegon 3.258 323.089
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.066
Ahold 3.538 74.353
Air France - KLM 1.025 35.298
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.052
Alfen 16 25.334
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.040
AMG 972 134.498
AMS 3 73
Amsterdam Commodities 305 6.746
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.066
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.015
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.358
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.641
ASML 1.766 110.544
ASR Nederland 21 4.514
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.109
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449